ATM program
Issued 2022
Total capacity
Sold to date
- Sales agent
- Agreement date
- Commission
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
DilutionScan read 28 of Arcturus Therapeutics Holdings Inc.'s SEC filings and found 1 ATM program, 2 shelf registrations and 3 completed offerings on file for ARCT. The latest dilution event on file is an offering on Nov 16, 2026. Analysis updated Nov 18, 2026.
ARCT
Unprofitable biotech with shrinking revenue
Arcturus is an unprofitable biotech burning through cash to develop RNA medicines. Revenue dropped 51% in FY 2025 to $67.2M, resulting in a $65.8M net loss and a $74.3M free cash flow burn.
Raise routes on file: active ATM + effective shelf · latest dilution event 2 days ago
The dominant contractual driver and its mechanism, then each further driver ranked.
Nov 16, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
From $29.99/mo. Signal8 Pro is $49/mo, or $40.67/mo billed yearly ($488/yr)
Deficiency notices, days under the minimum bid price, grace periods and listing rules, free with an account.
Shares outstanding, potential dilution and cash over time
Issued 2022
Total capacity
Sold to date
Issued 2025
Total capacity
Remaining
Issued 2022
Total capacity
Remaining
Issued 2026
Gross proceeds
Price per share
Issued 2026
Gross proceeds
Price per share
Gross proceeds
Price per share
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
From $29.99/mo. Signal8 Pro is $49/mo, or $40.67/mo billed yearly ($488/yr)
DilutionScanEvery instrument in full · From $29.99/mo
Covered companies in Biotechnology. All tickers A to Z